University of Chicago Medicine Comprehensive Cancer Center and Eli Lilly launched a two-year partnership aimed at expanding patient access to cancer clinical trials. The effort is designed to go beyond the traditional sponsor-site model and increase the share of trials available to patients outside routine care pathways. The program targets investigational therapies that may not yet be broadly accessible, focusing on removing operational barriers to trial participation. Both organizations framed the collaboration as a way to accelerate patient enrollment and improve continuity between cancer centers and drug developers. For developers, broadening access can reduce recruitment delays and strengthen data robustness across sites. For patients, the partnership can translate into earlier exposure to mechanism-driven therapies under investigation. Overall, the deal underscores how trial logistics is becoming an increasingly strategic lever for oncology pipelines.